Snavely M D, Ziegler M G, Insel P A
Endocrinology. 1985 Nov;117(5):2182-9. doi: 10.1210/endo-117-5-2182.
In the current studies, we have explored agonist-mediated down-regulation of adrenergic receptors in vivo. We infused catecholamines from sc implanted osmotic minipumps and examined the effects of the resultant increases in circulating levels of catecholamines on rat renal cortical alpha- and beta-adrenergic receptor subtypes, as assessed in radioligand binding studies. Infusion of epinephrine or norepinephrine (at 150 micrograms/kg X h) elevated plasma levels of each catecholamine 10- to 20-fold and decreased renal cortical alpha 1-receptor number about 50% without changing alpha 2-receptor number. Isoproterenol infusion (150 micrograms/kg X h) raised plasma levels of this catecholamine, but had no effect on the number of either alpha 1- or alpha 2-receptors. Renal cortical beta-adrenergic receptor number was decreased by infusion of all three catecholamines. However, the beta 1- and beta 2-adrenergic receptors were altered selectively by the different agonists. Infusion of norepinephrine decreased both beta 1- and beta 2-receptor number, but was more effective for the beta 1-receptors; this result was somewhat at variance with that we previously reported for rats bearing transplanted pheochromocytomas. The decrease in beta-receptor number due to epinephrine infusion was largely due to loss of the renal cortical beta 2-receptors. Infusion of isoproterenol decreased the number of both beta 1- and beta 2-receptors (69% and 75%, respectively). Infusion of norepinephrine maximally decreased the number of alpha 1-, beta 1-, and beta 2-receptors within 2 days, and the t 1/2 for receptor loss was about 12 h. beta-Receptors lost in response to isoproterenol infusion could not be recovered in a pellet prepared by high speed centrifugation of the supernatant derived from the preparation of renal cortical membranes. These results indicate that adrenergic receptor subtypes are differentially down-regulated by elevated levels of circulating catecholamines and that this differential loss of receptors depends on the nature of the receptor subtype, the agonist, and perhaps also whether catecholamines are infused rather than increased by pheochromocytoma.
在当前的研究中,我们探索了体内激动剂介导的肾上腺素能受体下调。我们通过皮下植入的渗透微型泵注入儿茶酚胺,并在放射性配体结合研究中评估了由此导致的儿茶酚胺循环水平升高对大鼠肾皮质α和β肾上腺素能受体亚型的影响。注入肾上腺素或去甲肾上腺素(150微克/千克×小时)可使每种儿茶酚胺的血浆水平升高10至20倍,并使肾皮质α1受体数量减少约50%,而α2受体数量不变。注入异丙肾上腺素(150微克/千克×小时)可提高该儿茶酚胺的血浆水平,但对α1或α2受体数量均无影响。注入所有三种儿茶酚胺均可使肾皮质β肾上腺素能受体数量减少。然而,β1和β2肾上腺素能受体被不同的激动剂选择性地改变。注入去甲肾上腺素可使β1和β2受体数量均减少,但对β1受体的作用更明显;这一结果与我们之前报道的移植嗜铬细胞瘤大鼠的结果略有不同。由于注入肾上腺素导致的β受体数量减少主要是由于肾皮质β2受体的丧失。注入异丙肾上腺素可使β1和β2受体数量均减少(分别为69%和75%)。注入去甲肾上腺素在2天内可最大程度地减少α1、β1和β2受体数量,受体丧失的半衰期约为12小时。因注入异丙肾上腺素而丧失的β受体无法在通过高速离心肾皮质膜制备物的上清液所制备的沉淀中恢复。这些结果表明,肾上腺素能受体亚型被循环儿茶酚胺水平升高差异性地下调,并且这种受体的差异性丧失取决于受体亚型的性质、激动剂,也许还取决于儿茶酚胺是通过注入而非嗜铬细胞瘤增加的。